Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAdGMTmExNJhLpAkplkNI5o4ib-vpBJtyfKDpnO0iA6fI#assertion>. }
Showing items 1 to 22 of
22
with 100 items per page.
- subject C0011777 "dexamethasone" assertion.
- subject C0001617 "corticosteroids" assertion.
- object C3885145 "sarilumab" assertion.
- object C1609165 "tocilizumab" assertion.
- subject C3540727 "corticosteroids" assertion.
- subject C3540726 "corticosteroids" assertion.
- subject C3540725 "corticosteroids" assertion.
- subject C3539185 "corticosteroids" assertion.
- subject C2983957 "IL-6" assertion.
- subject C1698754 "IL-6" assertion.
- subject C1527132 "IL-6" assertion.
- subject C1334122 "IL-6" assertion.
- subject C1149241 "IL-6" assertion.
- subject C0243077 "inhibitors" assertion.
- subject C0021760 "IL-6" assertion.
- predicate select?q=TRIPLE_UID:swcqhjom-TRIPLE-ABSTRACT-5 "include" assertion.
- object C1609931 "siltuximab" assertion.
- triple label "dexamethasone or other corticosteroids and IL-6 inhibitors including sarilumab , tocilizumab , and siltuximab" assertion.
- sentence label "Currently, there are FDA-approved therapies that attenuate the dysregulated inflammation that occurs in COVID-19 patients, such as dexamethasone or other corticosteroids and IL-6 inhibitors, including sarilumab, tocilizumab, and siltuximab." assertion.
- assertion wasGeneratedBy "S&T TWOC project version 1" assertion.
- version value "1" assertion.
- Triple-UID select?q=TRIPLE_UID:swcqhjom-TRIPLE-ABSTRACT-5 "swcqhjom-TRIPLE-ABSTRACT-5" assertion.